SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PTHS

Pelthos Therapeutics Inc. (New York Stock Exchange Arca:PTHS)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$6.38-$0.61 (-8.73%)
 
Market cap
$25.1M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 16, 2024
Market Cap$25.08M-76.8%
Revenue (ttm)$51.29M+592.6%
Net Income-$63.21M-168.1%
EPS-$18.62+49.9%
Shares Out3.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,962
Open$6.96
Previous Close$6.99
Day's Range$6.38 - $7.21
52-Week Range$6.02 - $31.62
Beta3.11
AnalystsBuy
Price Target$38.75(+507.37%)
Earnings DateMar 18, 2027
-7.30% (1D)
No price history available.

About PTHS

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Address
4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703, Durham, NC, 27703, US
Market Cap
25 million
Employees
92
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$486.27K
Bought
$999.98K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $38.33 (+500.8%)

1 firm rating PTHS in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From PTHS’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-8.73%
5 Days
-13.08%
1 Month
-67.43%
6 Months
-76.07%
1 Year
-76.83%

$PTHS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PTHS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PTHS's directors and management

Net Shares Purchased by Insiders−40k−20k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PTHS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

PTHS Revenue by Segment

$19.28MTotal
Commercial operations$15.21M78.91%
Change in fair value of convertible debt$4.07M21.09%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New PTHS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PTHS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PTHS

VTIVanguard Morningstar Total Stock Market ETF$577.85K
VXFVanguard Extended Market ETF$151.60K
IWCiShares Micro-Cap ETF$31.66K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from PTHS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: Analyst downgrades and fair value cuts dominate, though revenue growth in ZELSUVMI and Oppenheimer's maintained outperform partially offset bearish sentiment.

Recent Insider Activity

Buys
2
Sells
24
Buy Value
$999.98K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.